扶正消积方加减联合化疗治疗晚期非小细胞肺癌临床疗效观察

目的观察扶正消积方治疗晚期NSCLC的临床疗效。方法选取142例晚期NSCLC患者随机分为两组：治疗组67例（扶正消积方＋GP方案化疗），对照组75例（GP方案化疗），治疗4个周期后观察瘤灶变化、临床症状、Karnofskv评分、体重、不良反应及生存期。结果治疗组疾病控制率（83．58％）高于对照组（P〈0．05）；治疗组临床症状改善率（52．23％）明显优于对照组（P〈0．01）；治疗组生存质量改善优于对照组，（P〈0．01）；治疗组化疗期间胃肠道反应及骨髓抑制发生率低于对照组（P〈0．05）；治疗组1年生存率（53．73％）及中位生存期（13．33个月）均高于对照组（P〈0．05）。结论扶正消积方联合化疗治疗晚期NSCLC具有一定的减毒增效作用。

Clinical observation of advanced stage non-small-cell lung cancer treated by integrated FUZHENGXIAOJI Decoction and chemotherapy

Objective To estimate the clinical effect of FuzhengXiaoji Decoction and chemotherapy on advanced non- small-cell lung cancer （NSCLC） patients. Methods All of 142 NSCLC patients were randomized into two groups,the treatment group were treated with FuzhengXiaoji Decoction and chemotherapy with GP Protocol; the control group were only treated with chemotherapy, and then the clinical effect were evaluated by tumor-mass stable rate, symp~ toms, Karnofsky score, Weight, Adverse reactions and survival period after four cycles of treatment. Results The sta- ble rate on relieving tumor mass in treatment group was 83.58%, significantly higher than that in control group （P 〈 0.05）. The improvement rate of Clinical symptoms in treatment proup was 52.23% ,higher than that in the control group（P 〈 0.01 ）. The improvement of quality of life in treatment group was higher than that in control group（P 〈 0.01 ）. Incidence of gastrointestinal reaction and myelosuppression in treatment group was significantly lower than that in con- trol group （P 〈 0.05）. The sruvival rate in first year（53.73%） and median survival period （13.33 months） in treatment group were all higher than that in control group. Conclusion FuzhengXiaoji Decoction enhanced the efficacy of chemotherapy and reduced its side-effects in the treatment of advanced NSCLC laatients.